The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Risankizumab May Improve Symptoms of PsA

Risankizumab May Improve Symptoms of PsA

January 21, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Results from two recent phase 3 clinical trials, KEEPsAKE-1 and KEEPsAKE-2, show risankizumab (Skyrizi) improved skin and joint symptoms of patients in psoriatic arthritis (PsA).

You Might Also Like
  • Bimekizumab Improves Joint & Skin Symptoms in PsA Patients
  • Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
  • Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA
Explore This Issue
February 2021
Also By This Author
  • E6011 & Tocilizumab Monotherapy Studies Show Promising Results for RA Patients

In both studies, significantly more patients receiving treatment with risankizumab than placebo achieved the primary endpoint—a 20% improvement in disease activity defined by the ACR20 criteria at week 24, that is:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • A 20% improvement in the number of tender and number of swollen joints, and
  • A 20% improvement in three of the following five criteria:
    • Patient global assessment;
    • Physician global assessment;
    • Functional ability measure;
    • Visual analog pain scale; and
    • Erythrocyte sedimentation rate or C-reactive protein.

Ranked secondary endpoints for the studies included change from baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) and at least a 90% improvement on the Psoriasis Area Severity Index (PASI 90).

KEEPsAKE-1 examined PsA patients (N=964) with an intolerance to at least one disease modifying anti-rheumatic drug (DMARD) or who had had an inadequate response to at least one DMARD. KEEPsAKE-2 examined patients (N=443) who had an inadequate response or intolerance to biologic therapy and/or DMARDs. Patients were randomized to receive 150 mg of subcutaneous risankizumab or placebo.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: In KEEPsAKE-1 and KEEPsAKE-2, 57% and 51% of risankizumab-treated patients, respectively, achieved an ACR20 response at week 24 compared with 34% and 27%, respectively, of placebo-treated patients (P<0.001). The results of the ranked secondary endpoints at week 24 showed significant improvements in skin clearance, measured by PASI 90; physical function, measured by the HAQ-DI; and disease activity.

Additionally, in KEEPsAKE-1, the ranked secondary endpoint—the PsA Sharp/van der Heijde Score—was 0.23 in the risankizumab-treated and 0.32 placebo-treated groups (P=0.496). The lower score signifies less radiographic progression.

Rates of serious infections were similar between treatment groups, and no new safety signals were identified.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. AbbVie. News release: Risankizumab (Skyrizi) phase 3 results demonstrate improvements in disease activity across joint and skin symptoms among psoriatic arthritis patients. 2021 Jan 5.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: PsA, Psoriatic Arthritis, risankizumabIssue: February 2021

You Might Also Like:
  • Bimekizumab Improves Joint & Skin Symptoms in PsA Patients
  • Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
  • Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA
  • Guselkumab Approved for PsA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.